Moreover, TP53 mutations were significantly correlated with del17p cytogenetics, consistent with the literature.13 In line with previous studies, we report a high number of mutations in the mitogen-activated protein kinase signaling pathway with many, most often subclonal mutations in NRAS, KRAS and BRAF.13, 27 This suggests a striking subclonal convergence on this pathway in myeloma that may be exploited therapeutically. Here, TP53 is linked to plasma cell myeloma.